Denis Chem LabBOM:537536 +1.37%78 Net Margin % is 0.86% as of Mar. 2026, which is 81% below its 10-year median of 4.61. GuruFocus rates BOM:537536 with a GF Score™ of 78/100 and a GF Value™ of ₹118.26 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 953 Drug Manufacturers companies, Denis Chem Lab ranks worse than 52.99% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Denis Chem Lab's Net Income for the
three
months ended in Mar. 2026 was ₹4 Mil. Denis Chem Lab's Revenue for the
three
months ended in Mar. 2026 was ₹468 Mil. Therefore, Denis Chem Lab's net margin for the quarter that ended in Mar. 2026 was 0.86%.
The historical rank and industry rank for Denis Chem Lab's Net Margin % or its related term are showing as below:
BOM:537536'
s Net Margin % Range Over the Past 10 Years
Min: 1.1 Med: 4.61 Max: 6.65
Current: 4.63
BOM:537536's Net Margin % is ranked worse than 52.99% of 953
companies
in the Drug Manufacturers industry
Industry Median: 5.69
vs BOM:537536: 4.63
Denis Chem Lab (BOM:537536) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Denis Chem Lab Net Margin % Related Terms
Denis Chem Lab Net Margin % Historical Data
* Premium members only.
The historical data trend for Denis Chem Lab's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Denis Chem Lab's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Denis Chem Lab Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Denis Chem Lab's Net Margin % distribution charts can be found below:
* The bar in red indicates where Denis Chem Lab's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Denis Chem Lab (BOM:537536) has a Net Margin % of 0.86% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Denis Chem Lab and its competitors. This is 81% below median its historical median of 4.61. Over the past decade, Denis Chem Lab's Net Margin % has ranged from 1.10 to 6.65. According to the industry distribution chart, Denis Chem Lab ranks #505 out of 953 companies in the Drug Manufacturers industry, placing it in the top 53%.
Is Denis Chem Lab's Net Margin % too high?
Denis Chem Lab's current Net Margin % of 0.86% is 81% below median its 10-year median of 4.61. Over the past 10 years, this metric has ranged from a low of 1.10 to a high of 6.65. The Drug Manufacturers industry median Net Margin % is 5.69. Denis Chem Lab's value of 0.86% is 84.9% below this industry median. Based on the distribution chart, Denis Chem Lab ranks #505 out of 953 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Denis Chem Lab has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Denis Chem Lab's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Denis Chem Lab ranks #505 out of 953 companies for Net Margin %. This places Denis Chem Lab in the lower half of its industry. The industry median Net Margin % is 5.69. Denis Chem Lab's value of 0.86% is 84.9% below this benchmark. Historically, Denis Chem Lab's own Net Margin % has ranged from 1.10 to 6.65 over the past decade. While the company's 10-year median is 4.61 vs. the industry median of 5.69, Denis Chem Lab has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.69, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Denis Chem Lab's current Net Margin % of 0.86% is 84.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Denis Chem Lab and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Denis Chem Lab's current Net Margin % is 0.86%, which is 81% below median its own 10-year median of 4.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Denis Chem Lab stock overvalued right now?
Based on GuruFocus' analysis, Denis Chem Lab (BOM:537536) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹118.26, compared to a current price of ₹73.28 — trading 38% below its estimated fair value. The current Net Margin % is 0.86%, which is 81% below median its 10-year median of 4.61 and 84.9% below the Drug Manufacturers industry median of 5.69. Denis Chem Lab's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Denis Chem Lab (BOM:537536), the current Net Margin % is 0.86% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Denis Chem Lab (BOM:537536) Overvalued in 2026?
Based on GuruFocus' analysis, Denis Chem Lab stock appears to be undervalued.
The current stock price of ₹73.28 is trading 38% below its estimated GF Value™ of ₹118.26.
GuruFocus considers Denis Chem Lab to be Significantly Undervalued.
Key valuation signals for BOM:537536:
Net Margin %: 0.86% (81% below median its 10-year median of 4.61)
GF Value™: ₹118.26 vs. price of ₹73.28 (38% below fair value)
Industry Position: 84.9% below the Drug Manufacturers median (#505 of 953)
No single metric tells the full story. See the BOM:537536 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Denis Chem Lab Ltd is a pharmaceutical company involved in the manufacturing of pharmaceutical products. The company offers sterile intravenous injectables for human and veterinary use for different therapeutic areas. Its product portfolio includes antibiotic injections, diuretic injections, parenteral amino acid injections, plasma volume expanders, anti-pyretic Inj. irrigation solutions and dialysis solutions. The company has only one reportable segment which is Manufacturing, and Sales of Transfusion Solution in Bottles It generates its revenues through the sale of transfusion solution in bottles.
78GF Score
Get the complete analysis for BOM:537536
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:537536 has been successfully added to your 
